The anti‐CD19 CAR‐T cell therapies axicabtagene ciloleucel, lisocabtagene maraleucel, and tisagenlecleucel have demonstrated CR rates of 40%–58% as third‐line treatment in patients with R/R large B‐cell lymphomas, including DLBCL [42, 43, 44]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.